Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression

Area of Science:

• Hepatology
• Molecular Biology
• Signaling Pathways

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern with high mortality.
• The Hippo signaling pathway effectors, Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), regulate liver homeostasis.
• YAP/TAZ activation in non-cholangiocytes during chronic liver disease suggests a role in MASLD progression.

Purpose of the Study:

• To investigate the complex roles of YAP/TAZ in MASLD.
• To elucidate how YAP/TAZ dysregulation contributes to MASLD pathogenesis, including steatosis, inflammation, and fibrosis.
• To discuss the cell-type-specific functions of YAP/TAZ in various hepatic cells.

Main Methods:

• Literature review and analysis of existing studies on YAP/TAZ and MASLD.
• Exploration of molecular mechanisms underlying YAP/TAZ dysregulation in liver disease.
• Comparative analysis of YAP/TAZ functions across different hepatic cell types.

Main Results:

• YAP/TAZ dysregulation is a critical factor in MASLD progression.
• Aberrant YAP/TAZ activity contributes to hepatocyte dysfunction, inflammation, and fibrosis in MASLD.
• YAP/TAZ exhibit distinct roles in hepatocytes, hepatic stellate cells, macrophages, and biliary epithelial cells.

Conclusions:

• YAP/TAZ signaling plays a multifaceted role in both liver physiology and pathology.
• Targeting YAP/TAZ pathways may offer therapeutic strategies for MASLD.
• Further research into cell-specific YAP/TAZ functions is crucial for understanding and treating MASLD.